Literature DB >> 2521293

Activation/inactivation of human factor V by plasmin.

C D Lee1, K G Mann.   

Abstract

The effect of human plasmin on human coagulation factor V was studied using isolated proteins. Incubation of factor V with plasmin resulted in a rapid increase in procoagulant activity, followed by a subsequent decline in the ability of factor V to serve as a cofactor in the prothrombinase complex. Identical results were obtained when these reactions were conducted in the presence of dansylarginine-N-(3-ethyl-1,5-pentanediyl) amide (DAPA), indicating that the changes observed could not have occurred as a consequence of cleavage by alpha-thrombin. Analysis of the products of the reaction by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) revealed a temporal correlation between the rise and fall in factor V activity and the presence of several transient intermediates. These fragments are distinct from the subunits of alpha-thrombin-activated factor V (factor Va). The activation phase of the reaction was not significantly affected by the presence of phospholipid. In contrast, the rate of degradation of active fragments of factor V and the accompanying loss of activity were markedly enhanced in the presence of phospholipid vesicles. These data suggest that the action of plasmin upon factor V results in the transient formation of proteolytic fragments which express significant procoagulant activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521293

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Antithrombin agents as adjuncts to thrombolytic therapy.

Authors:  J K French; H D White
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

2.  Enhancing Thrombolysis with Adjunctive Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

3.  Thrombin Hypothesis: The TIMI 9B and GUSTO IIB Trials Have Successfully Disproven/Proven the Thrombin Hypothesis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

4.  Issues Regarding the Use of Heparin Following Streptokinase Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

5.  Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Coagul Disord       Date:  2010-07-01

Review 6.  Direct thrombin inhibitors as adjuncts to thrombolytic therapy.

Authors:  J K French; H D White
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 2.931

7.  Does plasmin have anticoagulant activity?

Authors:  Jane Hoover-Plow
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

8.  Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool.

Authors:  F Ayombil; S Abdalla; P B Tracy; B A Bouchard
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

Review 9.  The molecular basis of factor V and VIII procofactor activation.

Authors:  R M Camire; M H A Bos
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

Review 10.  Management of bleeding and coagulopathy following major trauma: an updated European guideline.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2013-04-19       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.